|
| Author | Year of publication | Country | No. of patients/eyes | Median/mean age of onset (months) | Most common presenting symptom (%) | % eyes with advanced ICRB groups D and E | % patients with EOE | Patient survival rate | Globe salvage rate for intraocular tumor | Follow-up time (median or mean) |
|
| Our study | 2018 | Thailand | 81/124 | 8 (1–48) | Leukocoria (76.5%) | 70.2% | 6.5% | 93.8% | 51.7% | 38 (0.2–148) months |
| Francis et al. [44] | 2018 | USA | 46/92 | 5.48 (median) (0.33–27.9) | NA | 48.9% | 6.52% | 97.83% | 91.30% | 38.7 (6.9–60.9) months |
| Goolam et al. [45] | 2018 | South Africa | 245/330 | 32.6 (mean) ± 26.8 | Leukocoria (37%) | 19% IRSS stage 0-1 | 69.39% | 58% | NA | 71.9 (3–238) months |
| Kaliki et al. [8] | 2017 | India | 1457/2074 | 24 (<1–370) | Leukocoria (75%) | 73% | 9% (eye) | 92% | 45% for all eyes | 30 (3–234) months |
| Al Hasan et al. [9] | 2017 | Syria | 37/65 | Age 4 months to 1 year in 40.6% | Leukocoria (57%) | NA | 13.50% | NA | NA | NA |
| Soliman et al. [7] | 2017 | Egypt | 47/70 | 24 (2–49) | Leukocoria (96%) | 64% | 0% | 100% | NA | NA |
| Berry et al. [46] | 2017 | USA | 294/345 | 19.8 (mean) | NA | Group D 47.8%; group E 52.2% | 0.9% (patient) | 98.5 | 40.3% | 86.3 (mean) ± 62.5 months |
| Li et al. [11] | 2016 | Taiwan | 154/NA | NA | NA | NA | NA | 83% | NA | NA |
| Gao et al. [12] | 2016 | China | 253/303 | 21 (0–611) | Leukocoria (71%) | 90% | 9% | 91% | 21.70% | 16 (0.3–119) months |
| Selistre et al. [10] | 2016 | Brazil | 140/187 | 23.5 (mean) | Leukocoria (74%) | 78% of all eyes | 36.40% | 86% | 29.30% | 323 (300–346) months |
| Chawla et al. [13] | 2016 | India | 600/794 | 21 (1–150) | Leukocoria (83%) | 78% | 27.70% | 76% | 28.2 | 21 (1–60) months |
| Lumbroso-Le Rouic et al. [15] | 2015 | France | 730/1049 | NA | NA | NA | NA | 98.5 | NA | 93 (median follow-up time) months |
| Gichico et al. [16] | 2015 | Kenya | 160 | NA | NA | NA | NA | 27% | NA | 37.5 (1–144) months |
| Waddell et al. [14] | 2015 | Uganda | 270/NA (181 before introduction of chemotherapy, 89 after introduction of chemotherapy) | NA | NA | 98% after introduction of chemotherapy had group E or EOE | NA | 45% (before introduction of chemotherapy) and 65% (after introduction of chemotherapy) | NA | 1–86 months |
| Okimoto et al. [19] | 2014 | Japan | 34/43 | 13 (0.7–74) | Leukocoria (97%) | 86% | 2.90% | 97% | 25.60% | 106.6 ± 53 months |
| Park et al. [18] | 2014 | Korea | 600/NA | NA | NA | NA | NA | 92% | NA | 10 years |
| da Rocha-Bastos et al. [22] | 2014 | Portugal | 46/59 | Mean age: 22.19 for unilateral, 6.92 for bilateral | Leukocoria (37%) | 54% Reese–Ellsworth IV-V | NA | 98% | 23.70% | 12 (1–33) years |
| Moreno et al. [20] | 2014 | Argentina | 438/577 | Unilateral: 35 for lower EHDI and 24 for higher EHDI. Bilateral: 11.5 for lower EHDI and 9 for higher EHDI | NA | NA | NA | 89% | NA | NA |
| Subramaniam et al. [17] | 2014 | Malaysia | 119/162 | 22 (1–123) | Leukocoria (92%) | NA | NA | 55% | NA | 1 year |
| Al-Nawaiseh I et al. [47] | 2014 | Jordan | 71/114 | 21.7 (mean) (1–276) | Leukocoria (54%) | 48% Reese–Ellsworth I–IV; 52% Reese–Ellsworth V | NA | NA | 63.2% | 26.9 (0.25–160) months |
| Lim et al. [23] | 2013 | Singapore | 51/67 | 25.7 (SD 19.9) | Leukocoria (71%) | 88% | 0% | 91% | 23.90% | 5 years |
| Nabie et al. [24] | 2012 | Iran | 40/57 | 20 (2 weeks–10.2 years) | Leukocoria (98%) | NA | NA | NA | 26.3% for all eyes | NA |
| Luna-Fineman S et al. [48] | 2012 | Central America | 171/213 | 28 (median) (1–108) | NA | 80% Reese–Ellsworth IV–V | 62% | 52% | NA | 18 (median) (1–112) months |
| Ali AAE et al. [49] | 2011 | Sudan | 25/31 | 36 (median) (8–60) | Enlarged eye (56%) | NA | 64% | 56% | NA | 15.4 (median) (9–36) months |
| Essuman et al. [27] | 2010 | Ghana | 23/27 | 24.0 ± 11.3 | Leukocoria (87%) | 87% Reese–Ellsworth V | 17% | 26% | NA | 5.7 months |
| Zhao et al. [25] | 2010 | China | 470/595 | 20 (2 weeks–10.2 years) | Leukocoria (73%) | NA | NA | NA | NA | NA |
| Atchaneeyasakul et al. [6] | 2009 | Thailand | 90/116 | 18 (0.5–80) | NA | 76% | 14% | 85% | 16% for all eyes | 27 months |
| Broaddus et al. [50] | 2009 | USA | 992/NA | NA | NA | NA | NA | 95% | NA | 5 years |
| MacCarthy et al. [28] | 2008 | Great Britain | 1576/2156 | NA | NA | NA | NA | Unilateral cases diagnosed: 1963–1967, 85%; 1998–2002, 97%. Bilateral cases diagnosed: 1963–1967, 88%; 1998–2002, 100% | NA | 5 years |
| Ozdemir et al. [29] | 2007 | Turkey | 91/121 | 18 (2–100) | Leukocoria (65%) | 79% Reese–Ellsworth IV-V | 20.9% | 92% | 46.3% for all eyes | 35 (4–63) months |
| Shields et al. [36] | 2006 | USA | 163/249 | NA | NA | 44% | 0 | 100% | 73.10% | 6.2 (1–10.6) years |
| Badhu et al. [30] | 2005 | Nepal | 43/47 | 3.04 ± 1.80 years | Proptosis (40%) | NA | 46.5% | 53.5% | NA | Minimum 2 years |
|
